Ben Hoffman, M.D. comments on a congressional investigation into the limited testing standards for car booster seat manufacturers.

Louis Picker, M.D., answers KATU-TV viewer questions about COVID-19 vaccination.

In a story about various potential COVID-19 vaccine options, Marcel Curlin, M.D., says: “It’s important to have options”; Mark Slifka, Ph.D., describes 90% vaccine efficacy as the “golden ceiling.”

Brandon Hayes-Lattin, M.D., participates in Committee on Childhood Cancers and Disability, co-authors report that finds Survivors of childhood cancer have an increased risk of experiencing disabling conditions, both from the cancer itself and from the effects of treatment. He says: “Recognizing that systems for both clinical care and for disability determinations change at the intersection of adolescence and young adulthood, the report’s findings on this transition for AYA cancer survivors is particularly meaningful.”

News coverage of new research by Marc Freeman, Ph.D., and colleagues revealing that injury or disease that afflicts a relatively small number of brain cells causes a chain reaction that stops activity across a vast network of neural circuits.

Mark Pennesi, M.D., Ph.D., describes gene editing to correct a blindness-causing mutation as “approaching a cure, because if you are able to cut out the mutation it is not going to come back.”

Louis Picker, M.D., describes his role as a member of the Western States Scientific Safety Review Workgroup. When asked if he’d receive COVID-19 vaccination when available, he says: “I'd put my arm out right now.”

Bruce Brauchard, Ph.D., has been named a fellow of the National Academy of Inventors.

Robert Macauley, M.D. comments on The Oregon Health Authority’s efforts to update its guidance for promoting health equity during resource constrained events. He says: “OHA’s commitment to developing principles to ensure all Oregonians — particularly communities of color, tribal communities and people with disabilities — have the resources they need is an important next step.”

A new study led by scientists at OHSU bolsters the scientific basis for mitochondrial replacement therapy in human clinical trials.